Cell News and Research

RSS

Study links PI3Kgamma molecule with multiple sclerosis

A University of Adelaide researcher has published results that suggest a possible new mechanism to control multiple sclerosis (MS).

5 Oct 2012

Blood clot-busting enzymes much busier than previously imagined

The body's blood clot-busting enzymes are much busier than previously imagined, with new research showing that they also dispose of every cell that dies prematurely from disease or trauma.

5 Oct 2012

Newborn mice use mum's unique odour to begin breastfeeding

Researchers show for the first time that a mammal begins to suckle its mother's milk through a learned response built on learning her unique combination of smells. When it is born, the newborn is exposed to the smell of its mother's amniotic fluid and the baby then responds to those smells to feed.

5 Oct 2012

New gene test can detect pre-cancerous cells in patients with mouth lesions

Researchers from Queen Mary, University of London have developed a new gene test that can detect pre-cancerous cells in patients with benign-looking mouth lesions. The test could potentially allow at-risk patients to receive earlier treatment, significantly improving their chance of survival.

5 Oct 2012

Patients with eye diseases can benefit from ArtCornea

Blindness is often caused by corneal diseases. The established treatment is a corneal transplant, but in many cases this is not possible and donor corneas are often hard to come by. In the future, an artificial cornea could make up for this deficiency and save the vision of those affected.

5 Oct 2012

Study reveals atomic-level structure of the human peptidase enzyme meprin β

An international research team led by the Spanish National Research Council (CSIC) and researchers from Kiel University revealed the atomic-level structure of the human peptidase enzyme meprin β (beta).

5 Oct 2012

Favorable preliminary results from XenoPort’s XP23829 Phase 1 trial on RRMS, psoriasis

XenoPort, Inc. announced today favorable preliminary results from a Phase 1 clinical trial in healthy adults designed to assess the pharmacokinetics (PK), safety and tolerability of single doses of four different oral formulations of XP23829, a novel fumaric acid ester compound that is a prodrug of monomethyl fumarate (MMF).

5 Oct 2012

UPMC Health Plan recognized for call center excellence

UPMC Health Plan has once again been recognized for call center excellence under the J.D. Power and Associates 2012 Call Center Certification Program.

5 Oct 2012

FDA licenses Quotient’s ALBAsera products

Quotient Biodiagnostics, Inc., a supplier of innovative and high-quality transfusion diagnostic products to hospitals, blood banks and other healthcare institutions, is pleased to announce that its range of ALBAsera Rare Antisera products have been licensed for sale by the U.S. Food and Drug Administration (FDA).

5 Oct 2012

CINJ physicians named among 2012 list of U.S. News Top Doctors

Several physicians at The Cancer Institute of New Jersey (CINJ), who are faculty members at the University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, have been named as a 'Top Doctor' by U.S. News & World Report.

5 Oct 2012

RNA clue to MS disease course

Researchers say that the RNA profiles of peripheral blood mononuclear cells can identify two distinct subsets of patients with multiple sclerosis.

4 Oct 2012

Antibiotic proved to be Achilles’ heel for some

US clinicians have identified patients at particular risk for Achilles injury while using quinolones.

4 Oct 2012

Loyola oncologist named ‘Heroes of Hope’ by Leukemia Research Foundation

The Leukemia Research Foundation has named Loyola University Medical Center oncologist Dr. Tulio Rodriguez one of its "Heroes for Hope."

4 Oct 2012

Mexiletine improves patient-reported stiffness in nondystrophic myotonia

An older medication originally approved to treat heart problems eases the symptoms of a very rare muscle disease that often leaves its sufferers stiff and in a good deal of pain, physicians and researchers report in the Oct. 3 issue of the Journal of the American Medical Association.

4 Oct 2012

New defibrillator offers advantages for young patients with congenital heart problems

A new ground-breaking technology was recently used at the University of Ottawa Heart Institute (UOHI) where two cardiologists, Dr. David Birnie and Dr. Pablo Nery, implanted a new innovative leadless defibrillator, the subcutaneous implantable cardioverter defibrillator (S-ICD), to a 18 year-old patient. Under Health Canada's special access program, this was only the third time this new type of ICD had been implanted in Canada.

4 Oct 2012

Long-term survivors of hematopoietic cell transplants more likely to develop heart disease

New research appearing online today in Blood, the Journal of the American Society of Hematology (ASH), suggests that long-term survivors of hematopoietic cell transplants (HCT) are at an increased risk of developing heart disease risk factors such as high blood pressure, diabetes, and high cholesterol when compared to the general population.

4 Oct 2012

New type of drug for drug-resistant cancer

New drug may be an effective alternative for patients whose cancer is resistant to currently available drugs.

4 Oct 2012

New nanodevice lays foundations for future development of novel therapies against aging

A team of Spanish scientists has developed an intelligent nanodevice that lays the foundations for the future development of new therapies against aging. The device consists of nanoparticles that can selectively release drugs in aged human cells.

4 Oct 2012

Assisted reproduction technology may increase risk of MS activity among women

Researchers in Argentina report that women with multiple sclerosis (MS) who undergo assisted reproduction technology (ART) infertility treatment are at risk for increased disease activity.

4 Oct 2012

Positive data from three Onconova Ex-RAD clinical trials on acute radiation syndrome

Onconova Therapeutics, Inc. today announced positive human safety, tolerability, and pharmacokinetic data from three clinical trials of Ex-RAD (recilisib sodium, ON 01210.Na), a novel radioprotectant being developed as a medical countermeasure for the treatment of acute radiation syndrome (ARS).

4 Oct 2012